On Monday, Disc Medicine earned an upgrade to its Relative Strength (RS) Rating, from 89 to 94.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an RS Rating north of 80 at the beginning of a new climb.
Disc Medicine is now considered extended and out of buy range after clearing a 66.61 buy point in a third-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company posted 0% earnings growth last quarter, while sales growth came in at 0%. Keep an eye out for the company's next round of numbers on or around Nov. 6.
The company earns the No. 100 rank among its peers in the Medical-Biomed/Biotech industry group. argenx ADR, Aurinia Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
